Argenx (ARGX) said Tuesday that its supplemental biologics license application for Vyvgart has received the US Food and Drug Administration's acceptance for priority review to treat adults with acetylcholine receptor antibody seronegative generalized myasthenia gravis.
The regulator has assigned May 10 as a Prescription Drug User Fee Act target action date, the company said.
The FDA's decision was based on Argenx's phase 3 Adapt Seron trial data, which evaluated the safety and efficacy of Vyvgart, Argenx said, adding that Vyvgart was "well-tolerated" with "consistent" safety profile.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments